ATE530635T1 - Verfahren und quantifizierungsassay zur bestimmung des c-kit/scf/pakt-status - Google Patents

Verfahren und quantifizierungsassay zur bestimmung des c-kit/scf/pakt-status

Info

Publication number
ATE530635T1
ATE530635T1 AT02753517T AT02753517T ATE530635T1 AT E530635 T1 ATE530635 T1 AT E530635T1 AT 02753517 T AT02753517 T AT 02753517T AT 02753517 T AT02753517 T AT 02753517T AT E530635 T1 ATE530635 T1 AT E530635T1
Authority
AT
Austria
Prior art keywords
amount
kit
biological
individual
scf
Prior art date
Application number
AT02753517T
Other languages
English (en)
Inventor
Sarah Bacus
Original Assignee
Ventana Med Syst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ventana Med Syst Inc filed Critical Ventana Med Syst Inc
Application granted granted Critical
Publication of ATE530635T1 publication Critical patent/ATE530635T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
AT02753517T 2001-08-21 2002-08-21 Verfahren und quantifizierungsassay zur bestimmung des c-kit/scf/pakt-status ATE530635T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31418801P 2001-08-21 2001-08-21
PCT/US2002/026811 WO2003016867A2 (en) 2001-08-21 2002-08-21 Method and quantification assay for determining c-kit/scf/pakt status

Publications (1)

Publication Number Publication Date
ATE530635T1 true ATE530635T1 (de) 2011-11-15

Family

ID=23218931

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02753517T ATE530635T1 (de) 2001-08-21 2002-08-21 Verfahren und quantifizierungsassay zur bestimmung des c-kit/scf/pakt-status

Country Status (8)

Country Link
US (2) US7419777B2 (de)
EP (2) EP2277991A1 (de)
JP (1) JP4204974B2 (de)
AT (1) ATE530635T1 (de)
AU (2) AU2007201809B2 (de)
CA (1) CA2457799C (de)
ES (1) ES2376422T3 (de)
WO (1) WO2003016867A2 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2266553T3 (es) 2001-06-29 2007-03-01 Ab Science Utilizacion de derivados de la n-fenil-2-pirimidina-amina para tratar las enfermedades inflamatorias.
ES2274993T3 (es) * 2001-06-29 2007-06-01 Ab Science Utilizacion de inhibidores de tirosina cinasa para el tratamiento de enfermedades alergicas.
JP2004537542A (ja) 2001-06-29 2004-12-16 アブ サイエンス 炎症性腸疾患（ｉｂｄ）を治療するための、チロシンキナーゼ阻害剤の使用
WO2003002109A2 (en) * 2001-06-29 2003-01-09 Ab Science Use of tyrosine kinase inhibitors for treating autoimmune diseases
WO2003003006A2 (en) * 2001-06-29 2003-01-09 Ab Science New potent, selective and non toxic c-kit inhibitors
US20040266797A1 (en) * 2001-06-29 2004-12-30 Alain Moussy Use of potent,selective and non toxic c-kit inhibitors for treating tumor angiogensis
US7381535B2 (en) * 2002-07-10 2008-06-03 The Board Of Trustees Of The Leland Stanford Junior Methods and compositions for detecting receptor-ligand interactions in single cells
US7393656B2 (en) * 2001-07-10 2008-07-01 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for risk stratification
EP1415156B1 (de) 2001-07-10 2009-09-02 The Board Of Trustees Of The Leland Stanford Junior University Verfahren und zusammensetzungen zum nachweis des aktivierungszustands multipler proteine in einzelzellen
US7695926B2 (en) * 2001-07-10 2010-04-13 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for detecting receptor-ligand interactions in single cells
US20030219772A1 (en) * 2001-09-28 2003-11-27 Kuyl Antoinette Cornelia Van Der Means and methods for treatment evaluation
US6944333B2 (en) * 2003-04-30 2005-09-13 Ventana Medical Systems, Inc. Color image compression via spectral decorrelation and elimination of spatial redundancy
GB0315991D0 (en) * 2003-07-08 2003-08-13 Dakocytomation Denmark As Standard
US8068988B2 (en) 2003-09-08 2011-11-29 Ventana Medical Systems, Inc. Method for automated processing of digital images of tissue micro-arrays (TMA)
WO2005027015A2 (en) * 2003-09-10 2005-03-24 Bioimagene, Inc. Method and system for quantitatively analyzing biological samples
ES2343840T3 (es) * 2003-11-04 2010-08-11 Bayer Healthcare Llc Procedimientos inmunohistoquimicos para supervisar los niveles de perk.
US7329495B2 (en) 2004-06-09 2008-02-12 Board Of Regents, The University Of Texas System Mutations in KIT confer imatinib resistance in gastrointestinal stromal tumors
AU2006206159A1 (en) * 2005-01-24 2006-07-27 Massachusetts Institute Of Technology Method for modeling cell signaling systems by means of bayesian networks
JP2008545959A (ja) * 2005-05-25 2008-12-18 スティフテルセン ウニヴェルジテーツフォルスクニング ベルゲン 顕微鏡装置および薬品、物理療法と生物学的危険物質のためのふるい分け（ｓｃｒｅｅｎｉｎｇ）方法
KR101667960B1 (ko) * 2007-07-25 2016-10-20 에자이 알앤드디 매니지먼트 가부시키가이샤 암 치료에서 이용하기 위한 멀티키나아제 억제제
EP2453234B1 (de) * 2007-10-29 2014-01-15 Eisai R&D Management Co., Ltd. Verfahren zur Vorhersage der Fähigkeit einer Zearalenon-Analogverbindung zur Behandlung von Krebs
JP5040597B2 (ja) 2007-11-06 2012-10-03 日本電気株式会社 評価システム、評価方法および評価プログラム
US20120270233A1 (en) * 2008-02-11 2012-10-25 Historx, Inc. Association of biomarkers with patient outcome
US20090269773A1 (en) * 2008-04-29 2009-10-29 Nodality, Inc. A Delaware Corporation Methods of determining the health status of an individual
US8399206B2 (en) 2008-07-10 2013-03-19 Nodality, Inc. Methods for diagnosis, prognosis and methods of treatment
US8227202B2 (en) 2008-07-10 2012-07-24 Nodality, Inc. Methods for diagnosis, prognosis and methods of treatment
US8557527B2 (en) * 2008-09-22 2013-10-15 Historx, Inc. Correlation of molecular markers with clinical outcome in GBM patients radiation treated with or without gefitinib
CA2749601C (en) 2009-01-14 2020-07-21 Stephen M. Hewitt Ratio based biomarkers and methods of use thereof
US20100303809A1 (en) * 2009-06-01 2010-12-02 Targeted Molecular Diagnostics, Llc Methods for the detection and quantitation of pten
US9540443B2 (en) 2011-01-26 2017-01-10 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies
NZ630363A (en) 2012-07-25 2018-09-28 Celldex Therapeutics Inc Anti-kit antibodies and uses thereof
CN113975386A (zh) 2014-05-23 2022-01-28 塞尔德克斯医疗公司 嗜酸性粒细胞或肥大细胞相关病症的治疗
WO2017051327A1 (en) * 2015-09-22 2017-03-30 Imageprovision Technology Pvt. Ltd. Method and system for detection and classification of particles based on processing of microphotographic images
US10436771B2 (en) * 2016-04-05 2019-10-08 The Board Of Trustees Of The Leland Stanford Junior University Systems and methods for targeted therapy based on single-cell stimulus perturbation response
AU2019265019B2 (en) 2018-05-11 2025-11-06 Beam Therapeutics Inc. Methods of substituting pathogenic amino acids using programmable base editor systems
GB201815123D0 (en) * 2018-09-17 2018-10-31 Micromass Ltd Tissue analysis
WO2021063388A1 (zh) * 2019-09-30 2021-04-08 武汉大学 c-Kit作为成瘾诊断及监测标志物和成瘾治疗靶点的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5288477A (en) * 1991-09-27 1994-02-22 Becton, Dickinson And Company Method for prognosticating response to cancer therapy
US5536642A (en) * 1993-09-09 1996-07-16 Barbera-Guillem; Emilio Diagnostic and prognostic methods for solid non-lymphoid tumors and their metastases
US5663315A (en) * 1994-12-06 1997-09-02 Alphagene, Inc. Isolated DNA encoding human GP2
EP0816848A1 (de) 1996-06-28 1998-01-07 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Verfahren zum vergleichenden Screenen von Substanzen mit pharmakologischer Wirkung
BR9907852A (pt) 1998-02-12 2000-10-24 Immunivest Corp Processos para detectar e enumerar células raras e cancerosas em uma população celular mista, para diagnosticar câncer de estágio precoce em um paciente de teste, para determinar a probabilidade de recorrência de câncer em um paciente humano anteriormente tratado de câncer, para distinguir um carcinoma confinado ao órgão de um carcinoma com propriedades metastáticas, para acompanhar a situação de remissão em um paciente humano com câncer que passa pelo tratamento de terapia contra o câncer e para aumentar quantidades de células epiteliais circulantes em uma amostra de sangue, partìcula magnética revestida, composição, conjuntos de teste para avaliar uma amostra de paciente quanto a presença de células raras circulantes, quanto a presença de células de tumor circulantes, quanto a presença de células de câncer de mama circulantes, quanto a presença de células de câncer de próstata circulantes, quanto a presença de células de câncer de cólon circulantes, quanto a presença de células de câncer de bexiga circulantes e para monitorar um paciente quanto a recorrência de câncer, e, fração de sangue periférico enriquecido quanto a células neoplásticas circulantes
EP1077724A2 (de) 1998-04-17 2001-02-28 The University Of Vermont Verfahren und produkte die mit metabolischen interaktionen in krankheiten zusammenhangen
CA2378008A1 (en) * 1999-06-28 2001-04-12 Source Precision Medicine, Inc. Systems and methods for characterizing a biological condition or agent using calibrated gene expression profiles
ATE331514T1 (de) * 1999-12-22 2006-07-15 Sugen Inc Indolinonderivate zur abänderung der c-kit tyrosinproteinkinase
ATE271691T1 (de) 2000-01-12 2004-08-15 Ventana Med Syst Inc Verfahren zum nachweis der effektivität einer krebstherapie
US6406669B1 (en) 2001-01-12 2002-06-18 The Regents Of The University Of California Polyaniline-based optical ammonia detector

Also Published As

Publication number Publication date
EP1427810B9 (de) 2012-04-25
JP4204974B2 (ja) 2009-01-07
US9625446B2 (en) 2017-04-18
EP2277991A1 (de) 2011-01-26
ES2376422T3 (es) 2012-03-13
AU2010241288A1 (en) 2010-11-25
WO2003016867A2 (en) 2003-02-27
CA2457799C (en) 2014-05-27
AU2010241288B2 (en) 2012-05-31
WO2003016867A3 (en) 2003-08-28
CA2457799A1 (en) 2003-02-27
AU2007201809B2 (en) 2010-08-05
EP1427810B1 (de) 2011-10-26
US7419777B2 (en) 2008-09-02
EP1427810A2 (de) 2004-06-16
EP1427810A4 (de) 2005-02-02
US20080182276A1 (en) 2008-07-31
AU2007201809A1 (en) 2007-05-17
JP2005527781A (ja) 2005-09-15
US20030045451A1 (en) 2003-03-06

Similar Documents

Publication Publication Date Title
ATE530635T1 (de) Verfahren und quantifizierungsassay zur bestimmung des c-kit/scf/pakt-status
WO2008060651A3 (en) Sparc and methods of use thereof
WO2002003075A3 (en) Methods for detecting activity of clotting factors
DK2216416T3 (da) Fremgangsmåder til detektering af nukleinsyresekvenser i urin
WO2003066876A3 (en) An apparatus and methods for using biological material to discriminate an agent
EE05675B1 (et) Meetod konformse haiguse diagnoosimiseks v?i tuvastamiseks, selleks vajalik katsemenetlus, reaktiivikomplekt ning seade
WO2004063704A3 (en) Vitamin d assay
EP1495139A4 (de) Verfahren und zusammensetzungen zum nachweis und zur quantifizierung von nukleinsäureanalyten
DE60138829D1 (de) Verfahren zur unterscheidung des reizkolons von der entzündlichen darmerkrankung (inflammatory bowel disease, ibd) und zur überwachung von patienten mit ibd unter verwendung von endogenem gesamt-lactoferrin als marker
WO2001057272A3 (en) Human genome-derived single exon nucleic acid probes useful for analysis of gene expression in human placenta
DE60233574D1 (de) Verfahren und zusammensetzungen zum nachweis des aktivierungszustands multipler proteine in einzelzellen
WO2005084109A3 (en) Cancer specific gene mh15
WO2007135568A3 (en) A METHOD FOR PREDICTING RESPONSIVENESS TO TNFα BLOCKING AGENTS
WO2006044748A3 (en) RESPONSE PREDICTORS FOR ErbB PATHWAY-SPECIFIC DRUGS
DE602004028892D1 (de) Testtablett und Testsystem zur Bestimmung der Reaktionsantwort einer biologischen Probe
EP2662453A3 (de) Nachweis und Behandlung von Schizophrenie
SG156625A1 (en) Method for measuring resistance or sensitivity to docetaxel
ZA200706670B (en) Method for determining responsiveness to CHK1 inhibitors
ATE285073T1 (de) Elispot-verfahren zur quantifizierung der aktivität von menschlichen und tierischen zellen, zur insbesondere blutzellen
WO2003087761A3 (en) Molecular profiling of disease and therapeutic response using phospho-specific antibodies
WO2005068655A3 (en) Methods of assessing a tissue inflammatory response using expression profiles of endothelial cells
DE60130565D1 (de) Pde8a und seine verwendung
IL137865A0 (en) Method for the diagnosis and follow-up of schizophrenia
WO2003023056A3 (en) Specific markers for multiple sclerosis
WO2003005028A8 (fr) Procede de selection d'agents bio-actifs par couplage de luminescence et systeme cellulaire vivant pour la mise en oeuvre de ce procede

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties